Evidence map›Paper›PMID 35849547›Full record

ArticleMolecular pharmaceutics2022

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter

Adrianna Cytryniak, Kinga Żelechowska-Matysiak, Ewa Nazaruk, Renata Bilewicz, Rafał Walczak, Emilia Majka, Adam Mames, Frank Bruchertseifer, Alfred Morgenstern, Aleksander Bilewicz and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Adrianna CytryniakFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.
Kinga Żelechowska-MatysiakCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Ewa NazarukFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.
Renata BilewiczFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.ORCID 0000-0003-0058-3691
Rafał WalczakCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Emilia MajkaCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Adam MamesInstitute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland.
Frank BruchertseiferDirectorate for Nuclear Safety and Security, European Commission, Joint Research Centre, Postfach 2340, 76125 Karlsruhe, Germany.
Alfred MorgensternDirectorate for Nuclear Safety and Security, European Commission, Joint Research Centre, Postfach 2340, 76125 Karlsruhe, Germany.
Aleksander BilewiczCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Agnieszka Majkowska-PilipCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0001-9449-6411

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we propose tailored lipid liquid-crystalline carriers (cubosomes), which incorporate an anticancer drug (doxorubicin) and complexed short-lived α-emitter (bismuth-213), as a strategy to obtain more effective action toward the cancer cells. Cubosomes were formulated with doxorubicin (DOX) and an amphiphilic ligand (DOTAGA-OA), which forms stable complexes with

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsDoxorubicinDrug CarriersDrug LiberationHumansLigandsLipidsParticle SizeAntineoplastic AgentsDoxorubicinDrug CarriersLigandsLipids213Bi radionuclidecancer cellscubosomescytotoxicitydoxorubicinα-therapy

Identifiers

PMID35849547
PMCPMC9346610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.